HYFT - MindWalk Therapeutics Total Debt to Capital

Public company logo of MindWalk Holdings (HYFT)

The price trend for MindWalk Holdings (HYFT), a progressive developer of AI tools for corporate analytics, shows a metric at 0.50. Demand for such SaaS products is moderately dependent on economic cycles, as companies' drive to optimize costs through automation stabilizes revenues. At the same time, the business relies on a narrow segment of molecule and medical data search, making its financial condition dependent on pharmaceutical grants.

HYFT: MindWalk Holdings Inc. Total Debt to Capital 09/05/2025 - 11/01/2026
Core merchandise of MindWalk Therapeutics

MindWalk Holdings (HYFT) competes in the high-tech sector of AI diagnostics and medical digitalization, where scaling requires significant capital expenditures. By analyzing financial leverage through the debt-to-equity ratio, an investor assesses the proportion of borrowed funds within the asset financing structure relative to equity, which determines the business's level of dependence on creditors and the sustainability of its long-term development strategy.

Competitor analysis for MindWalk Holdings

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|PRGO - Debt to Equity|All Debt to Shareholders' Equity Ratio ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Debt to Equity|Total Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital mannkindcorp.com|Total Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - All Debt to Shareholders' Equity Ratio|Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Debt to Capital|AQST: Total Debt to Equity Ratio|scPharmaceuticals Inc. - Aggregate Debt to Capital|TECX: Total Debt to Capital|Tonix Pharma - All Debt to Shareholders' Equity Ratio|SXTC (SXT Pharmaceuticals) - Total Debt to Capital|Debt to Capital Eupraxia Pharma EPRX|Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Oramed Pharmaceuticals Inc. ORMP|ENTX - Total Debt to Equity Ratio|ABVC BioPharma Inc - Total Debt to Capital|Total Debt to Capital Coefficient Cumberland Corp CPIX|Quantum BioPharma Ltd (QNTM) - Debt to Equity|Debt to Equity Ratio FGEN|TELO (Telomir Pharmaceuticals, Inc.) - Total Debt to Capital|Debt to Equity Ratio RANI (Rani Therapeutics Inc)|Total Debt to Equity Ratio SNYR (Synergy CHC Corp)|Total Debt to Equity Ratio rallybio.com RLYB|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|Total Debt to Capital pulmatrix.com PULM|PTHL - Debt to Equity|APM: Debt to Equity|Lyra Therapeutics, Inc (LYRA) - Debt to Equity|Impact BioMedical, Inc. (IBO) - Total Debt to Capital|Total Debt to Equity Ratio TNFA|YCBD: All Debt to Shareholders' Equity Ratio|Total Debt to Capital PRFX|CYTO (altamiratherapeutics.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Lipella LIPO|OptiNose Corp (OPTN) - Debt to Capital|PIRS - Debt to Equity|PROC: Debt to Equity|PTPI: Total Debt to Capital|Debt to Equity Ratio QLI|SLRN (ACELYRIN, Inc.) - Total Debt to Capital|TFF Pharmaceuticals, Inc (TFFP) - Total Debt to Capital Coefficient